RxDoctor Payments Data

Michael Collier, MD

Internal Medicine · Knoxville, TNNPI 1811933674

Payments from drug & device makers

$16,656in general payments, 2019–2025

Across 1,317 payments — averaging $12.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$2K
  • Pfizer$2K
  • GSK$1K
  • Amgen$1K
  • Lilly USA, LLC$915
  • plus $7K from 54 others

What the payments were for

  • Food & beverage$16,611100%
  • Education$450%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)209$2,417
Novo Nordisk220$2,322
Pfizer144$1,767
GSK93$1,185
Amgen(2 entities)109$1,169
Lilly USA, LLC82$915
AstraZeneca40$568
Boehringer Ingelheim42$508
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC31$438
Amarin Pharma, Inc.30$371
Novartis22$318
Merck29$295
Otsuka America Pharmaceutical, Inc.18$273
Xeris Pharmaceuticals, Inc.12$235
Takeda Pharmaceuticals U.S.A., Inc.16$222
Astellas Pharma US Inc11$195
Lundbeck LLC10$191
Radius Health, Inc.10$172
Dexcom, Inc.8$168
E.r. Squibb & Sons, L.L.C.10$162
Jazz Pharmaceuticals Inc.7$139
Antares Pharma, Inc.6$132
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)7$132
Sumitomo Pharma America, Inc.7$120
Abbott8$114
Exact Sciences7$110
Daiichi Sankyo Inc.5$109
Kowa Pharmaceuticals America, Inc.8$104
Heartflow, Inc.2$101
Esperion Therapeutics, Inc.6$99
Biohaven Pharmaceutical Holding Company Ltd.6$97
Edwards Lifesciences4$96
Phathom Pharmaceuticals, Inc.5$94
Teva Pharmaceuticals USA, Inc.7$90
Clarus Therapeutics Inc.13$82
Medtronic(3 entities)4$80
Idorsia Pharmaceuticals US Inc5$78
Bayer5$77
Sanofi-aventis U.S. LLC5$74
Gilead5$74
Biohaven Pharmaceuticals, Inc.5$69
Johnson & Johnson4$58
Regeneron Healthcare Solutions, Inc.4$58
Arbor Pharmaceuticals, Inc.3$48
Eisai Inc.3$48
IBSA Pharma Inc.3$46
Vanda Pharmaceuticals Inc.2$41
Shire North American Group Inc2$32
Dynavax Technologies Corporation2$29
Mycovia Pharmaceuticals, Inc.1$21
Corium, LLC1$20
Bioventus LLC1$19
W. L. Gore & Associates, Inc.1$19
Scilex Pharmaceuticals Inc.1$18
Shield Therapeutics Inc1$18
Bausch Health US, LLC1$18
Valeritas, Inc.1$18
Philips North America LLC1$17
Supernus Pharmaceuticals, Inc.1$17
Seqirus USA Inc1$17

How this compares

$16,656 in reported general payments places this provider in the 95th percentile of 2,216 internal medicine providers in Tennessee.

See all internal medicine providers in Tennessee

Medicare billing

Part B allowed, 2024
$319,241
Medicare patients
485
Services billed
44,695

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide129$192,047
EliquisApixaban96$125,580
GlyxambiEmpagliflozin/Linagliptin54$67,495
JardianceEmpagliflozin29$44,520
XareltoRivaroxaban26$40,034
Tresiba Flextouch U-200Insulin Degludec26$34,790
Trelegy ElliptaFluticasone/Umeclidin/Vilanter26$34,789
FarxigaDapagliflozin Propanediol18$26,651
Repatha SureclickEvolocumab37$24,114
Janumet XrSitagliptin Phos/Metformin Hcl21$21,096
MounjaroTirzepatide15$20,069
JanuviaSitagliptin Phosphate12$18,591
Breo ElliptaFluticasone/Vilanterol24$17,542
LinzessLinaclotide16$17,040
Tresiba Flextouch U-100Insulin Degludec17$16,903

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$2,322$192,047129 claims
PfizerEliquis, Abrysvo, Premarin$1,767$132,724121 claims
Boehringer IngelheimGlyxambi, Jardiance, Stiolto Respimat$508$121,21195 claims
GSKTrelegy Ellipta, Breo Ellipta, Shingrix$1,185$60,75788 claims
Johnson & JohnsonXarelto$58$40,03426 claims
MerckJanumet Xr, Januvia$295$39,68733 claims
AstraZenecaFarxiga$568$26,65118 claims
AbbVieLinzess, Synthroid$2,417$20,998100 claims
Lilly USA, LLCMounjaro$915$20,06915 claims
Astellas Pharma US IncMyrbetriq$195$14,67215 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,216 internal medicine providers in Tennessee.

Other internal medicine in Knoxville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →